It occurs in approximately 40% to 60% of patients; in R/R ALL, 30% to 60% of patients relapse after CAR-T-cell therapy, of which 10% to 20% are CD19-negative relapses.74,75. Here, CD19 is linked to acute lymphoblastic leukemia.